Purple Biotech Valuation
Is PPBT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PPBT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate PPBT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate PPBT's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PPBT?
Key metric: As PPBT is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is PPBT's PB Ratio? | |
|---|---|
| PB Ratio | 0.2x |
| Book | US$29.41m |
| Market Cap | US$4.80m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does PPBT's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.9x | ||
TKUN Tikun Olam-Cannbit Pharmaceuticals | 1.9x | n/a | ₪25.9m |
YBRD Y.B Urban Renewal - Residential Development | 3.8x | n/a | ₪29.4m |
PMCN-M Pharmocann Global | 16.8x | n/a | ₪3.8m |
SEMG Seach Medical Group | 1.1x | n/a | ₪95.7m |
PPBT Purple Biotech | 0.2x | n/a | ₪17.6m |
Price-To-Book vs Peers: PPBT is good value based on its Price-To-Book Ratio (0.2x) compared to the peer average (5.9x).
Price to Book Ratio vs Industry
How does PPBT's PB Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price-To-Book vs Industry: PPBT is good value based on its Price-To-Book Ratio (0.2x) compared to the Asian Pharmaceuticals industry average (2.1x).
Price to Book Ratio vs Fair Ratio
What is PPBT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 0.2x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate PPBT's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Evogene
₪39.8m
Operates as a computational biology company.
EVGN
₪5.86
7D
-8.7%
1Y
-73.2%
Protalix BioTherapeutics
US$112.5m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
PLX
US$7.33
7D
-0.1%
1Y
97.5%
Rekah Pharmaceutical Industry
₪163.3m
Engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel.
REKA
₪14.31
7D
0%
1Y
-12.6%